NVST
Envista Holdings Corp
NYSE · Healthcare · Medical - Equipment & Services · US
$27.28
−1.12%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.9B | 2.7B | 2.5B | 2.6B | 2.6B |
| Cost of Revenue | 1.3B | 1.2B | 1.1B | 1.1B | 1.1B |
| Gross Profit | 1.6B | 1.5B | 1.4B | 1.5B | 1.5B |
| Operating Expenses | |||||
| R&D Expense | 120.8M | 114.0M | 99.1M | 93.8M | 100.1M |
| SG&A Expense | 1.2B | 1.2B | 1.1B | 1.0B | 1.0B |
| General & Admin Expense | 296.3M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 1.2B | 295.9M | 40.7M |
| Total Operating Expenses | 1.3B | 1.3B | 2.4B | 1.4B | 1.2B |
| Cost and Expenses | 2.6B | 2.5B | 3.5B | 2.5B | 2.2B |
| Operating Income (EBIT) | 283.4M | 225.7M | (1.0B) | 31.5M | 319.2M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 20.6M | 36.6M | 46.4M | 63.4M | 38.4M |
| Net Interest Income | (20.6M) | (36.6M) | (46.4M) | (63.4M) | (38.4M) |
| Other Non-Op Income/Expense | (49.3M) | (48.5M) | (46.5M) | (86.4M) | (35.3M) |
| Non-Operating Income (excl Interest) | 28.7M | 11.9M | (1.2B) | (295.9M) | (40.7M) |
| EBT (Pre-Tax Income) | 234.1M | 177.2M | (1.1B) | (54.9M) | 283.9M |
| Income Tax Expense | 139.1M | 130.2M | 33.9M | 45.3M | 45.9M |
| Bottom Line | |||||
| Net Income | 95.0M | 47.0M | (1.1B) | (100.2M) | 243.1M |
| Earnings from Cont. Ops | 95.0M | 47.0M | (1.1B) | (100.2M) | 238.0M |
| Earnings from Discont. Ops | — | — | — | — | 5.1M |
| Bottom Line Net Income | 95.0M | 47.0M | (1.1B) | (100.2M) | 238.0M |
| Per Share | |||||
| Basic EPS | $0.59 | $0.28 | ($6.50) | ($0.60) | $1.46 |
| Diluted EPS | $0.58 | $0.28 | ($6.50) | ($0.60) | $1.34 |
| Revenue Per Share | $17.64 | $16.19 | $14.58 | $15.38 | $15.77 |
| Shares | |||||
| Basic Shares Outstanding | 161.9M | 168.0M | 172.2M | 166.9M | 162.9M |
| Diluted Shares Outstanding | 164.1M | 169.2M | 172.2M | 166.9M | 177.6M |
| Profitability Metrics | |||||
| EBITDA | 351.3M | 329.8M | 279.5M | 463.0M | 497.7M |
| D&A | 96.6M | 116.0M | 123.1M | 135.6M | 137.8M |
| EBIT | 254.7M | 213.8M | 156.4M | 327.4M | 359.9M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jul 1, 2026